How I Treat Relapsed/Refractory Follicular LymphomaMartin, PeterClinical Advances in Hematology & Oncology
Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented challenges for hematologists for decades. Despite numerous clinical studies, outcomes are consistently disappointing with 5-year overall survival rates of approximately 10%. Allogeneic hematopoietic cell transplantation at the ...
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia Am J Hematol, 94 (10) (2019), pp. E253-E255 View in ScopusGoogle Scholar 43 I Aldoss, D Yang, A Aribi, et al. Efficacy of the combination of venetoclax and...
Although great progress has been made in ITP management during the last decade, there are still unmet needs with regard to the short- and long-term efficacy in many relapsed or refractory cases. A multicenter retrospective cohort study indicated that patients who failed splenectomy, rituximab, romip...
Although great progress has been made in ITP management during the last decade, there are still unmet needs with regard to the short- and long-term efficacy in many relapsed or refractory cases. A multicenter retrospective cohort study indicated that patients who failed splenectomy, rituximab, romip...
What Kind of Myeloma Does Talvey Treat? Talvey treats multiple myeloma that has come back after previous therapy (relapsed) or did not go away after previous therapy (refractory) in people who have received at least four different types of treatment. How Will I Get Talvey? Talvey is give...
We're learning more about the craving that fuels self-defeating habits—and how new discoveries can help us kick the habit.
How Do I Use Darzalex? How Well Does It Treat Multiple Myeloma? 7 min read Introduction Darzalex (daratumumab) is used for treating a blood cancer called multiple myeloma. Darzalex may be used to treat multiple myeloma that has never been treated, is relapsed, meaning the cancer came back ...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy, but older patients are at higher risk of relapsed disease as they may not be eligible for full-intensity frontline chemoimmunotherapy or have comorbidities that limit standard treatments. Recent years have brought more ...
She was successfully treated with steroids, but relapsed 6 months after discontinuation (Hb, 6.9 g/dL; WBCs, 8.9 × 109/L; lymphocytes, 5.2 × 106/mL; LDH, 2.2 ULN; reticulocytes, 205 × 109/L; unconjugated bilirubin, 2.9 mg/dL; and DAT confirmed positive for IgG alone). Flow ...